EGFR and non-small cell lung carcinoma: Sesumi et al. [47] and Soucheray et al. [48] directed NSCLC HCC4006 cells to EGFR T790M-driven resistance to gefitinib and erlotinib by pharmacologically inhibiting the otherwise recurrently observed EMT resistance mechanism.